Click here to get this post in PDF
Bringing any pharmaceutical product to market is a feat that takes time and effort. It takes years of development, research and analysis before a product can be considered ready for release. At every step of the process, developers must ensure stringent processes are followed to ensure that the product is developed in the correct manner, does not cause undue harm to those it is meant to help, and that records are kept to demonstrate that all the relevant safety protocols have been followed. This includes ensuring the regulations in the country of development and the country of release are met. Here, we ask the experts at Alderley Analytical to tell us more about testing requirements centred on immunogenicity.
Immunogenicity Testing – What Is it?
The development of biopharmaceuticals is a complex task. One typical complexity is the need for immunogenicity testing, which ensures that proteins introduced into the human body do not trigger unwanted immune system responses. But what does this mean in the regulatory context? Below, we examine the crux of immunogenicity, explore testing requirements, and discuss how companies can effectively navigate this complicated yet important regulatory landscape.
Understanding Immunogenicity
Immunogenicity is the ability of a chemical, usually a protein, to prompt an immune response in the human body. Testing for this is vital for the safety and efficacy of biopharmaceuticals. Unexpected immune reactions can lessen a drug’s impact and, in some cases, lead to harmful consequences. Such issues can jeopardise the entire drug development programme.
What Tests Are Involved?
Immunogenicity analysis usually includes multiple tests. These can include the following:
- Screening tests – Theses are designed to detect the presence of anti-drug antibodies (ADAs)
- Confirmatory tests – This can be used to confirm the specificity of positive ADAs
- Titration – These help to check the level of ADA present
- Neutralising antibody tests – These help to check the level of ADA inhibition of a drug’s activity
- Cell based tests – These can help in detection and characterisation of antibodies that neutralise the drug’s function
Each test performed plays an integral part in helping developers understand how the immune system reacts to treatments they are developing.
A complete and rigorous testing process is both a regulatory requirement and a moral issue, as it is vital to ensuring drug safety and efficacy.
Immunogenicity Testing Requirements in the UK
Developers in the UK must be aware of international standards for immunogenicity testing. These are guided in no small part by the 2019 guidance produced by the US Food and Drug Administration (FDA). The FDA framework emphasises a risk-based approach. It details documentation requirements and highlights the importance of an integrated immunogenicity summary report. Keeping accurate documentation helps stakeholders understand the potential immunological challenges and develop strategies to mitigate them.
Navigating Regulatory Compliance
To comply with the accepted guidelines, a company must implement a holistic strategy to ensure it understands the immunogenicity risk assessment guidelines, implements rigorous bioanalytical strategies, and fully understands the nuances of clinical study design. The guidance mentioned above can help by clarifying method development, validating test results, and accurately documenting and reporting such testing.
Addressing Challenges in Immunogenicity Testing
One issue certainly dominates immunogenicity testing. Some organisations may face challenges in differentiating between pre-existing antibodies in humans and those antibodies that have been realised because of the treatment. However, the FDA’s guidance provides tried-and-tested models for statistical analysis and reporting.
Future Trends in Immunogenicity Testing Regulations
Scientific understanding and regulatory expectations will evolve as we move into the future. Due to this, companies must keep up-to-date with innovations and changes in immunogenicity testing. This will involve investment in training, research, and development as well as investment in a company’s agility to adapt to any new guidelines. The front and centre should always ensure the safe and effective development of products.
To sum up, navigating the regulatory landscape of immunogenicity testing is a vital part of biopharmaceutical development. By being aware of and understanding current guidelines and anticipating future trends, a company can ensure its products meet the highest standards of safety and efficacy.
You may also like:
What Laboratory Specimen Labels Are, And How To Properly Use Them
Image source: Depositphotos.com
